Analyst Consensus ?
ConsensusBuy49 ratings
Bullish2857.1%
Neutral2142.9%
Bearish00.0%
Hilton Worldwide Holdings Inc. · HLT · FY2025 Q2 · Calendar Q3 2025
Hilton sustains growth plans despite RevPAR pressure and China weakness
The supplied analysis supports a constructive but qualified growth case: Hilton's asset-light expansion, conversion pipeline, luxury and lifestyle brands, and emerging-market development provide operating support, while modest RevPAR pressure, China weakness, and execution around conversions remain important offsets.
Reported Before market openNYSEConsumer Cyclical
$73.50B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.20
Consensus $2.05
EPS surprise
+7.3%
Reported versus consensus
Reported revenue
$3.14B
Consensus $3.10B
Revenue surprise
+1.3%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-2.6%
Event window
SPY move
+0.9%
Same window
Abnormal move
-3.4%
Stock minus SPY
Volume
1.7×
Versus trailing sessions
Subsequent drift
+1.1%
Up to 20 sessions
HLTSPY benchmark
Ask FN2 about HLT FY2025 Q2
Transcript, numbers and history already loaded
Why did HLT fall 2.6% after beating EPS estimates in FY2025 Q2?What changed in HLT's guidance and outlook in FY2025 Q2?Give me the bull and bear case for HLT after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, Hilton reported stronger scale indicators: adjusted EBITDA exceeded $1 billion, net unit growth accelerated to 7.5%, and the pipeline expanded beyond 510,000 rooms. Management also introduced LivSmart Studios and highlighted further luxury, lifestyle, and emerging-market expansion, while maintaining the prior full-year RevPAR and net-unit-growth framework.
Guidance delta
Maintained: full-year RevPAR guidance remained flat to +2%, with net unit growth targeted at 6%-7%.
Key takeaways
- Management described adjusted EBITDA above $1 billion despite a modest system-wide RevPAR decline.
- Net unit growth reached 7.5%, while the development pipeline exceeded 510,000 rooms.
- Luxury and lifestyle expansion, conversions, and emerging-market development remain central to the growth plan.
- The company plans approximately $3.3 billion of shareholder returns in 2025.
Management priorities
- Continue luxury and lifestyle expansion, including new Waldorf Astoria and Conrad properties.
- Roll out LivSmart Studios and add lifestyle brands designed to support conversions.
- Pursue signings and construction to support 6%-7% full-year net unit growth.
- Expand in India, Africa, and Saudi Arabia while monitoring demand in China and the U.S.
Follow HLT with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$326.56Current
$135Low
$276.91Average
$379High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 11, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Sep 10, 2026 |
| Susquehanna | Neutral | Neutral | Maintain | Aug 11, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 30, 2026 |
| Macquarie | Neutral | Neutral | Maintain | Jul 29, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 29, 2026 |
| Baird | Outperform | Outperform | Maintain | Jul 29, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 21, 2026 |
| Evercore ISI Group | Outperform | In Line | Upgrade | Jul 21, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 17, 2026 |
| Bernstein | Market Perform | Market Perform | Maintain | May 15, 2026 |
| UBS | Buy | Buy | Maintain | Apr 30, 2026 |
| Mizuho | Neutral | Neutral | Maintain | Apr 29, 2026 |
| Goldman Sachs | Buy | Neutral | Upgrade | Dec 15, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Jul 30, 2025 |
| B of A Securities | Buy | Buy | Maintain | Jul 21, 2025 |
| Jefferies | Buy | Hold | Upgrade | May 12, 2025 |
| TD Cowen | Buy | Buy | Maintain | Oct 24, 2024 |
| Melius Research | Hold | Buy | Downgrade | Oct 21, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Aug 8, 2024 |
| HSBC | Buy | Buy | Maintain | Apr 3, 2024 |
| BMO Capital | Market Perform | Market Perform | Maintain | Mar 20, 2024 |
| Citigroup | Neutral | Buy | Downgrade | Dec 14, 2022 |
| Redburn Partners | Neutral | Neutral | Maintain | Nov 30, 2022 |
| Berenberg | Buy | Hold | Upgrade | Sep 15, 2022 |
| Argus Research | Buy | Buy | Maintain | Dec 28, 2021 |
| Gordon Haskett | Hold | Hold | Maintain | Jun 26, 2020 |
| Nomura Instinet | Buy | Buy | Maintain | Jun 23, 2020 |
| Nomura | Buy | Buy | Maintain | Jun 23, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 8, 2020 |
| RBC Capital | Sector Perform | Outperform | Downgrade | Mar 30, 2020 |
| Longbow Research | Neutral | Buy | Downgrade | Jul 15, 2019 |
| Argus | Hold | Buy | Downgrade | Nov 5, 2018 |
| B. Riley Securities | Buy | Neutral | Upgrade | Oct 25, 2018 |
| B. Riley FBR | Buy | Neutral | Upgrade | Oct 25, 2018 |
| Cowen & Co. | Outperform | Outperform | Maintain | Oct 23, 2018 |
| B. Riley | Neutral | Neutral | Maintain | Apr 27, 2018 |
| FBR Capital | Neutral | Outperform | Downgrade | Oct 27, 2017 |
| Tigress Financial | Neutral | Neutral | Maintain | Apr 27, 2017 |
| Guggenheim | Neutral | Neutral | Maintain | Apr 26, 2017 |
| Telsey Advisory Group | Perform | Outperform | Downgrade | Apr 3, 2017 |
| Bank of America | Buy | Neutral | Upgrade | Dec 15, 2016 |
| MKM Partners | Buy | Sell | Upgrade | Dec 5, 2016 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Jul 28, 2016 |
| Wolfe Research | Outperform | Outperform | Maintain | Jul 6, 2016 |
| CLSA | Buy | Buy | Maintain | Apr 12, 2016 |
| Brean Capital | Buy | Buy | Maintain | Jun 10, 2015 |
| Credit Suisse | Outperform | Outperform | Maintain | Nov 21, 2014 |
| Craig-Hallum | Buy | Hold | Upgrade | May 23, 2014 |
| ISI Group | Neutral | Neutral | Maintain | Jan 21, 2014 |
Named analyst price targets
Upside is calculated against the persisted current price $326.56. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Patrick Scholes | $316 | $308.66 | -3.2% | Sep 10, 2026 |
| UBS | Robin Farley | $363 | $324.99 | +11.2% | Aug 14, 2026 |
| Deutsche Bank | Analyst unavailable | $365 | $314.66 | +11.8% | Aug 12, 2026 |
| Barclays | Analyst unavailable | $368 | $322.43 | +12.7% | Jul 29, 2026 |
| Barclays | Brandt Montour | $367 | $321.32 | +12.4% | Jul 20, 2026 |
| Wells Fargo | Analyst unavailable | $379 | $328.48 | +16.1% | Jul 16, 2026 |
| Bernstein | Richard Clarke | $320 | $316.56 | -2.0% | May 15, 2026 |
| Morgan Stanley | Analyst unavailable | $319 | $315.92 | -2.3% | May 12, 2026 |
| UBS | Analyst unavailable | $371 | $323.98 | +13.6% | Apr 30, 2026 |
| Truist Financial | Analyst unavailable | $312 | $315.74 | -4.5% | Apr 29, 2026 |
| Susquehanna | Analyst unavailable | $353 | $323.34 | +8.1% | Apr 29, 2026 |
| Barclays | Analyst unavailable | $365 | $323.34 | +11.8% | Apr 29, 2026 |
| Evercore ISI | Analyst unavailable | $350 | $335.07 | +7.2% | Apr 24, 2026 |
| Susquehanna | Analyst unavailable | $345 | $333.67 | +5.6% | Apr 23, 2026 |
| Barclays | Analyst unavailable | $363 | $328.91 | +11.2% | Apr 16, 2026 |
| Morgan Stanley | Stephen Grambling | $318 | $321.31 | -2.6% | Apr 10, 2026 |
| UBS | Analyst unavailable | $360 | $315.96 | +10.2% | Feb 22, 2026 |
| Truist Financial | Patrick Scholes | $307 | $326.1 | -6.0% | Feb 12, 2026 |
| Barclays | Analyst unavailable | $350 | $332.91 | +7.2% | Feb 12, 2026 |
| Mizuho Securities | Analyst unavailable | $321 | $325.13 | -1.7% | Feb 12, 2026 |
| Wells Fargo | Analyst unavailable | $373 | $329.82 | +14.2% | Feb 12, 2026 |
| Jefferies | David Katz | $339 | $326.55 | +3.8% | Feb 11, 2026 |
| Evercore ISI | Analyst unavailable | $325 | $296.46 | -0.5% | Jan 22, 2026 |
| Morgan Stanley | Analyst unavailable | $306 | $301.86 | -6.3% | Jan 16, 2026 |
| Barclays | Analyst unavailable | $309 | $301.86 | -5.4% | Jan 16, 2026 |
| Bernstein | Analyst unavailable | $304 | $287.73 | -6.9% | Jan 6, 2026 |
| Goldman Sachs | Analyst unavailable | $317 | $280.05 | -2.9% | Dec 15, 2025 |
| Truist Financial | Analyst unavailable | $253 | $271.08 | -22.5% | Oct 23, 2025 |
| Deutsche Bank | Analyst unavailable | $287 | $275.06 | -12.1% | Oct 23, 2025 |
| Susquehanna | Analyst unavailable | $255 | $275.06 | -21.9% | Oct 23, 2025 |
| Goldman Sachs | Lizzie Dove | $285 | $275.06 | -12.7% | Oct 23, 2025 |
| Barclays | Brandt Montour | $297 | $271.99 | -9.1% | Oct 23, 2025 |
| Morgan Stanley | Analyst unavailable | $289 | $265.96 | -11.5% | Oct 22, 2025 |
| Robert W. Baird | Analyst unavailable | $275 | $258.23 | -15.8% | Oct 17, 2025 |
| Barclays | Analyst unavailable | $288 | $258.91 | -11.8% | Oct 3, 2025 |
| Bernstein | Analyst unavailable | $288 | $266.41 | -11.8% | Sep 17, 2025 |
| Raymond James | Analyst unavailable | $300 | $273.29 | -8.1% | Jul 30, 2025 |
| Morgan Stanley | Stephen Grambling | $286 | $274.34 | -12.4% | Jul 15, 2025 |
| Mizuho Securities | Ben Chaiken | $263 | $258.74 | -19.5% | Feb 5, 2025 |
| Wells Fargo | Daniel Politzer | $240 | $258.74 | -26.5% | Feb 4, 2025 |
| Truist Financial | Patrick Scholes | $220 | $233.5 | -32.6% | Oct 24, 2024 |
| Deutsche Bank | Carlo Santarelli | $200 | $233.5 | -38.8% | Oct 24, 2024 |
| Evercore ISI | Duane Pfennigwerth | $240 | $238.81 | -26.5% | Oct 21, 2024 |
| Barclays | Brandt Montour | $244 | $238.47 | -25.3% | Oct 18, 2024 |
| Robert W. Baird | Michael Bellisario | $235 | $237.49 | -28.0% | Oct 17, 2024 |
| Goldman Sachs | Lizzie Dove | $245 | $220.38 | -25.0% | Sep 18, 2024 |
| Bernstein | Richard Clarke | $261 | $217.08 | -20.1% | Aug 29, 2024 |
| Macquarie | Chad Beynon | $208 | $205.07 | -36.3% | Aug 7, 2024 |
| Barclays | Brandt Montour | $228 | $228.19 | -30.2% | Jul 17, 2024 |
| Argus Research | John Staszak | $260 | $228.47 | -20.4% | Jul 16, 2024 |
| Truist Financial | Patrick Scholes | $209 | $203.57 | -36.0% | Apr 25, 2024 |
| Macquarie | Chad Beynon | $205 | $203.86 | -37.2% | Apr 25, 2024 |
| Deutsche Bank | Carlo Santarelli | $185 | $203.98 | -43.3% | Apr 25, 2024 |
| Robert W. Baird | Michael Bellisario | $215 | $204.7 | -34.2% | Apr 25, 2024 |
| Barclays | Brandt Montour | $216 | $198.82 | -33.9% | Apr 19, 2024 |
| HSBC | Meredith Jensen | $254 | $210.37 | -22.2% | Apr 3, 2024 |
| Wells Fargo | Jeffrey Donnelly | $200 | $210.51 | -38.8% | Mar 20, 2024 |
| Evercore ISI | Diane Pfenningwerth | $210 | $210.51 | -35.7% | Mar 20, 2024 |
| Robert W. Baird | Michael Bellisario | $210 | $204.66 | -35.7% | Mar 15, 2024 |
| Barclays | Brandt Montour | $168 | $147.44 | -48.6% | Mar 9, 2023 |
| Morgan Stanley | Analyst unavailable | $167 | $145.82 | -48.9% | Feb 7, 2023 |
| Wells Fargo | Analyst unavailable | $148 | $147.98 | -54.7% | Feb 2, 2023 |
| Barclays | Analyst unavailable | $139 | $136.05 | -57.4% | Dec 15, 2022 |
| Citigroup | Analyst unavailable | $148 | $138.11 | -54.7% | Dec 14, 2022 |
| Truist Financial | Analyst unavailable | $147 | $140.28 | -55.0% | Dec 5, 2022 |
| Morgan Stanley | Analyst unavailable | $171 | $141.42 | -47.6% | Dec 5, 2022 |
| Truist Financial | Analyst unavailable | $62 | $140.65 | -81.0% | Nov 15, 2022 |
| UBS | Analyst unavailable | $159 | $129.83 | -51.3% | Aug 3, 2022 |
| UBS | Robin Farley | $157 | $132.85 | -51.9% | May 17, 2022 |
| Morgan Stanley | Analyst unavailable | $144 | $145.38 | -55.9% | May 4, 2022 |
| Morgan Stanley | Analyst unavailable | $143 | $157.02 | -56.2% | May 2, 2022 |
| Wells Fargo | Dori Kesten | $160 | $150.67 | -51.0% | Feb 26, 2022 |
| Macquarie | Chad Beynon | $138 | $150.41 | -57.7% | Feb 20, 2022 |
| Morgan Stanley | Thomas Allen | $135 | $143.39 | -58.7% | Jan 30, 2022 |
| Evercore ISI | Richard Hightower | $155 | $144.52 | -52.5% | Jan 18, 2022 |
| Bernstein | Richard Clarke | $161 | $148.61 | -50.7% | Jan 10, 2022 |
| Argus Research | John Staszak | $178 | $155.02 | -45.5% | Dec 28, 2021 |
| Loop Capital Markets | Daniel Adam | $142 | $139.59 | -56.5% | Dec 2, 2021 |
| Truist Financial | Patrick Scholes | $139 | $146.04 | -57.4% | Oct 28, 2021 |
Track every rating change on HLT the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationHilton Worldwide Holdings Inc., a hospitality company, engages in managing, franchising, and leasing hotels and resorts. It operates in two segments, Management and Franchise, and Ownership. The company engages in the hotel management and licensing of its brand names, trademarks, and service marks. It operates a brand portfolio of luxury, lifestyle, full service, focused service, all-suites hotel, and timeshare under the Waldorf Astoria Hotels & Resorts, LXR Hotels & Resorts, Conrad Hotels & Resorts, Signia by Hilton, NoMad, Canopy by Hilton, Graduate by Hilton, Tempo by Hilton, Motto by Hilton, Hilton Hotels & Resorts, DoubleTree…
Historical context
All HLT earningsConsumer Cyclical peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| NKE NIKE, Inc. | FY2027 Q1 · Calendar Q4 2026 | +10.0% | -0.7% | Nike’s performance categories grow as resets weigh on FY27 outlook |
| CCL Carnival Corporation & plc | FY2026 Q3 · Calendar Q3 2026 | +5.9% | +13.4% | Carnival posts record Q3 as demand and efficiency offset fuel costs |
| DRI Darden Restaurants, Inc. | FY2027 Q1 · Calendar Q3 2026 | 0.0% | -3.0% | Darden reaffirms FY2027 outlook as brands deliver mixed comp growth |
| AZO AutoZone, Inc. | FY2026 Q4 · Calendar Q3 2026 | +3.6% | +3.3% | AutoZone pairs commercial momentum with an aggressive FY2027 expansion plan |
| LEN-B Lennar Corporation | FY2026 Q3 · Calendar Q3 2026 | — | — | Lennar: Efficiency Gains Offset Housing-Market Pressures |
| LEN Lennar Corporation | FY2026 Q3 · Calendar Q3 2026 | — | -4.1% | Lennar Holds Volume Guidance as Margins Improve Despite Housing Headwinds |
Latest beats and misses
Who reports nextBeat on EPS
Get the HLT recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
- Polygon adjusted daily market bars · 2026-10-10T20:50:44.044371+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-10T20:50:44.041412+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-10. For educational purposes only; not investment advice.